The Diagnosis Division of Roche Romania expects RON 90 million turnover in 2011

The Diagnostics Division of Roche Romania has announced its results for the past year and its expectations for future development, through a press conference held today. In 2010, the company registered a 10.2 percent increase in turnover against 2009, reaching RON 86.9 million. Expectations for the year to come are moderate, as Harald Wolf, country manager at Roche Romania Diagnostics Division, expects a value of RON 90 million in sales this year. Moreover, the company has announced the availability of a new test for the detection of HPV.

At the press conference, Dr. Mihaela Badea, managing director at Micomi clinic, stated that cervical cancer is one of the most serious diseases that nowadays society is being faced with. In Romania, it is the second cause of death for women, after breast cancer. Thus, 2,000 deaths are registered in Romania yearly, while a total of 15,000 patients suffering from this disease are kept in evidence locally.

Marcel Gmuender, head of EMEA Subregion 1, Roche Diagnostics, and Dr Badea emphasized the necessity of personalized medical care nowadays. “Although the complete potential of personalized medicine has not yet been accomplished, in the medical practice there is already a series of approaches demonstrating the paradigm change and the gradual passing from a generalized approach to targeted, personalized treatments and therapies guided by an answer,” stated Gmuender. He also added that science and research will continue to evolve, in spite of a common belief that scientific discoveries have reached a peak.

The Diagnostics Division of Roche has been on the Romanian market for two years, since May 2009. It currently holds 75 employees, covering the entire area of the country, of which 27 were recruited last year.